

ASX Announcement

Funding Update

Sydney, Australia, 16 January 2019: Further to the Funding Update announcement made to the market on 18 December 2018 by Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**), regarding a short term loan provided by a director of the Company, the Company wishes to provide the following update.

The Company is currently reviewing a number of potential funding options to support the Company's future capital requirements. At this stage, the Company has not entered into or approved any funding arrangement which has not previously been announced to the market.

As soon as the Company has finalised any funding arrangement and is in a position to announce such an arrangement, it will update the market accordingly.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA